Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Other GLP-1 Agonists Based on published clinical trial data, here's how retatrutide's side effect profile compares: Key observations: Retatrutide shows similar or lower GI side effect rates compared to maximum doses of competing peptides The glucagon receptor component doesn't appear to significantly increase side effect burden Discontinuation rates are comparable across all three agents Heart rate effects may be slightly lower with retatrutide The takeaway: retatrutide's trial-reported safety profile is at or below semaglutide and high-dose tirzepatide on the metrics that matter nausea, diarrhea, vomiting, discontinuation
It is important to note that this will align with what many non-users are already looking for
As researchers explore new therapeutic approaches, GLP-1 receptor agonistsmedications originally developed for type 2 diabetes and obesityhave emerged as a potential off-label treatment
In a 15-month longitudinal clinical trial*, patients who were receiving tirzepatide were significantly more likely to achieve weight loss, and their changes in weight were larger at 3 months, 6 months, and 12 months in comparison to patients taking semaglutide
The treatment duration should be tailored to achieve and maintain the desired weight loss while ensuring patient safety
